サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1376369

抗核抗体検査市場：製品、手法、技術、適応症、エンドユーザー別-2023-2030年の世界予測

Antinuclear Antibody Testing Market by Product, Technique (Enzyme-linked immunosorbent assay, Indirect immunofluorescent, Multiplex immunoassay), Technology, Indication, End-User - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗核抗体検査市場：製品、手法、技術、適応症、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年10月16日
発行: 360iResearch
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗核抗体検査市場は、2022年の16億米ドルから2030年には35億6,000万米ドルに達すると予測され、予測期間中のCAGRは10.45%です。

抗核抗体検査の世界市場

主な市場の統計
市場金額：基準年[2022] 16億米ドル
推定市場金額[2023] 17億7,000万米ドル
予測市場金額[2030] 35億6,000万米ドル
CAGR（%） 10.45%
抗核抗体検査 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗核抗体検査市場の評価に不可欠なツールです。事業戦略と製品満足度に関連する主要指標を分析し、ベンダーを包括的に評価します。これにより、ユーザーは特定のニーズに合わせた情報に基づいた意思決定を行うことができます。高度な分析により、ベンダーは4つの象限に分類され、それぞれ成功のレベルが異なります：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。この洞察に満ちたフレームワークにより、意思決定者は自信を持って市場をナビゲートすることができます。

市場シェア分析

市場シェア分析では、ベンダーの市場情勢に関する貴重な洞察を提供します。全体収益、顧客ベース、その他の主要指標への影響を評価することで、企業の業績と直面する競合環境を包括的に理解することができます。この分析では、調査期間中の市場シェア獲得、断片化、優位性、業界再編などの競合レベルも明らかにします。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業の市場力学と製品に関する包括的な情報を提供します。

2.市場の開拓度：新興市場と成熟市場セグメントへの浸透度を詳細に分析し、有利なビジネスチャンスを浮き彫りにします。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報。

4.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関するインテリジェントな洞察。

本レポートは、以下のような主要な質問に対応しています：

1.抗核抗体検査市場の市場規模および予測は？

2.抗核抗体検査市場で最も高い投資ポテンシャルを持つ製品、セグメント、用途、分野は？

3.抗核抗体検査市場における競争戦略の窓とは？

4.抗核抗体検査市場の最新技術動向と規制の枠組みは？

5.抗核抗体検査市場における主要ベンダーの市場シェアは？

6.抗核抗体検査市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口における自己免疫疾患の有病率の上昇
      • 自己免疫疾患に対する意識を高めるための政府プログラム
      • ヘルスケア費の増大とヘルスケアインフラの近代化
    • 抑制要因
      • 抗核抗体検査の精度の問題
    • 機会
      • 全自動抗核抗体IIAの高い可能性
      • 抗核抗体パターン認識におけるAIとMLの新たな応用
    • 課題
      • 厳格で時間のかかるANA製品の承認手続き
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗核抗体検査市場：製品別

  • 試薬およびアッセイキット
  • サービス
  • ソフトウェア

第7章 抗核抗体検査市場：技術別

  • 酵素結合免疫吸着検定法（ELISA）
  • 間接免疫蛍光法（IIF）
  • マルチプレックスイムノアッセイ

第8章 抗核抗体検査市場：技術別

  • 自動テスト
  • 手動テスト

第9章 抗核抗体検査市場適応症別

  • 若年性特発性関節炎（JIA）
  • 関節リウマチ
  • 強皮症
  • シェーグレン症候群
  • 全身性エリテマトーデス（SLE）
  • 全身性血管炎

第10章 抗核抗体検査市場：エンドユーザー別

  • 臨床検査室
  • 診断センター
  • 病院

第11章 南北アメリカの抗核抗体検査市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域の抗核抗体検査市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカの抗核抗体検査市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第15章 競争力のあるポートフォリオ

  • 主要企業プロファイル
    • Abbott Laboratories
    • Abcam PLC
    • Antibodies Incorporated
    • Arthrex, Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BIOGENIX INC. PVT. LTD.
    • Boston Scientific Corporation
    • Erba Mannheim
    • EUROIMMUN Medizinische Labordiagnostika AG
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Immuno Concepts NA Ltd.
    • Immunodiagnostic Systems
    • Inova Diagnostics, Inc.
    • Laboratory Corporation of America Holdings
    • Organogenesis Inc.
    • PerkinElmer, Inc.
    • Quidel Corporation
    • Siemens Healthineers AG
    • Smith+Nephew PLC
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • ZEUS Scientific, Inc
    • Zimmer Biomet Holdings, Inc
  • 主要な製品ポートフォリオ

第16章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTINUCLEAR ANTIBODY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. ANTINUCLEAR ANTIBODY TESTING MARKET DYNAMICS
  • FIGURE 7. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 8. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2022 VS 2030 (%)
  • FIGURE 10. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
  • FIGURE 12. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
  • FIGURE 14. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 16. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 18. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 20. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 25. ANTINUCLEAR ANTIBODY TESTING MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 26. ANTINUCLEAR ANTIBODY TESTING MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ANTINUCLEAR ANTIBODY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY REAGENTS & ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 10. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDIRECT IMMUNOFLUORESCENT (IIF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS (JIA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SJOGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY SYSTEMIC VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. ANTINUCLEAR ANTIBODY TESTING MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. ANTINUCLEAR ANTIBODY TESTING MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. ANTINUCLEAR ANTIBODY TESTING MARKET LICENSE & PRICING
目次
Product Code: MRR-69324464D119

The Antinuclear Antibody Testing Market is projected to reach USD 3.56 billion by 2030 from USD 1.60 billion in 2022, at a CAGR of 10.45% during the forecast period.

Global Antinuclear Antibody Testing Market

KEY MARKET STATISTICS
Base Year Value [2022] USD 1.60 billion
Estimated Year Value [2023] USD 1.77 billion
Forecast Year Value [2030] USD 3.56 billion
CAGR (%) 10.45%
Antinuclear Antibody Testing Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Antinuclear Antibody Testing Market.

Based on Product, market is studied across Reagents & Assay Kits, Services, and Software. The Reagents & Assay Kits is projected to witness significant market share during forecast period.

Based on Technique, market is studied across Enzyme-linked immunosorbent assay (ELISA), Indirect immunofluorescent (IIF), and Multiplex immunoassay. The Enzyme-linked immunosorbent assay (ELISA) is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Automated Testing and Manual Testing. The Automated Testing is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis, Scleroderma, Sjogren's Syndrome, Systemic Lupus Erythematosus (SLE), and Systemic Vasculitis. The Sjogren's Syndrome is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Clinical Laboratories, Diagnostic Centers, and Hospitals. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Antinuclear Antibody Testing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Antinuclear Antibody Testing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Antinuclear Antibody Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, Antibodies Incorporated, Arthrex, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., BIOGENIX INC. PVT. LTD., Boston Scientific Corporation, Erba Mannheim, EUROIMMUN Medizinische Labordiagnostika AG, F. Hoffmann-La Roche Ltd., Grifols, S.A., Immuno Concepts NA Ltd., Immunodiagnostic Systems, Inova Diagnostics, Inc., Laboratory Corporation of America Holdings, Organogenesis Inc., PerkinElmer, Inc., Quidel Corporation, Siemens Healthineers AG, Smith + Nephew PLC, Thermo Fisher Scientific Inc., Trinity Biotech PLC, ZEUS Scientific, Inc, and Zimmer Biomet Holdings, Inc.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Antinuclear Antibody Testing Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Antinuclear Antibody Testing Market?

3. What is the competitive strategic window for identifying opportunities in the Antinuclear Antibody Testing Market?

4. What are the latest technology trends and regulatory frameworks in the Antinuclear Antibody Testing Market?

5. What is the market share of the leading vendors in the Antinuclear Antibody Testing Market?

6. Which modes and strategic moves are suitable for entering the Antinuclear Antibody Testing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antinuclear Antibody Testing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune diseases among population
      • 5.1.1.2. Government programs to create awareness for autoimmune diseases
      • 5.1.1.3. Growing healthcare expenditure and modernization of healthcare infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with accuracy of antinuclear antibody tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Higher potential of fully automated antinuclear antibody IIA
      • 5.1.3.2. Emerging applications of AI and ML in antinuclear antibody pattern recognition
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and time consuming ANA product approval procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antinuclear Antibody Testing Market, by Product

  • 6.1. Introduction
  • 6.2. Reagents & Assay Kits
  • 6.3. Services
  • 6.4. Software

7. Antinuclear Antibody Testing Market, by Technique

  • 7.1. Introduction
  • 7.2. Enzyme-linked immunosorbent assay (ELISA)
  • 7.3. Indirect immunofluorescent (IIF)
  • 7.4. Multiplex immunoassay

8. Antinuclear Antibody Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. Automated Testing
  • 8.3. Manual Testing

9. Antinuclear Antibody Testing Market, by Indication

  • 9.1. Introduction
  • 9.2. Juvenile Idiopathic Arthritis (JIA)
  • 9.3. Rheumatoid Arthritis
  • 9.4. Scleroderma
  • 9.5. Sjogren's Syndrome
  • 9.6. Systemic Lupus Erythematosus (SLE)
  • 9.7. Systemic Vasculitis

10. Antinuclear Antibody Testing Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinical Laboratories
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals

11. Americas Antinuclear Antibody Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Antinuclear Antibody Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Antinuclear Antibody Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

  • 15.1. Key Company Profiles
    • 15.1.1. Abbott Laboratories
    • 15.1.2. Abcam PLC
    • 15.1.3. Antibodies Incorporated
    • 15.1.4. Arthrex, Inc.
    • 15.1.5. Becton Dickinson and Company
    • 15.1.6. Bio-Rad Laboratories, Inc.
    • 15.1.7. BIOGENIX INC. PVT. LTD.
    • 15.1.8. Boston Scientific Corporation
    • 15.1.9. Erba Mannheim
    • 15.1.10. EUROIMMUN Medizinische Labordiagnostika AG
    • 15.1.11. F. Hoffmann-La Roche Ltd.
    • 15.1.12. Grifols, S.A.
    • 15.1.13. Immuno Concepts NA Ltd.
    • 15.1.14. Immunodiagnostic Systems
    • 15.1.15. Inova Diagnostics, Inc.
    • 15.1.16. Laboratory Corporation of America Holdings
    • 15.1.17. Organogenesis Inc.
    • 15.1.18. PerkinElmer, Inc.
    • 15.1.19. Quidel Corporation
    • 15.1.20. Siemens Healthineers AG
    • 15.1.21. Smith + Nephew PLC
    • 15.1.22. Thermo Fisher Scientific Inc.
    • 15.1.23. Trinity Biotech PLC
    • 15.1.24. ZEUS Scientific, Inc
    • 15.1.25. Zimmer Biomet Holdings, Inc
  • 15.2. Key Product Portfolio

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing